



## **Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017**

November 8, 2017

WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2017 London Healthcare Conference on November 15, 2017 at 2:00 p.m. GMT (9:00 a.m. EST).

The presentation will be web cast and accessible through the investor relations section of the Company's web site, <http://ir.minervaneurosciences.com>.

### **About Minerva Neurosciences:**

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit [www.minervaneurosciences.com](http://www.minervaneurosciences.com).

### **Contact:**

William B. Boni  
VP, Investor Relations/  
Corp. Communications  
Minerva Neurosciences, Inc.  
(617) 600-7376

Source: Minerva Neurosciences, Inc